The Union Health Ministry has proposed bringing antimicrobials under central regulatory oversight, in a move aimed at strengthening checks on the quality, safety and efficacy of the medicines and slowing the spread of antimicrobial resistance.
The ministry has proposed an amendment to the New Drugs and Clinical Trials Rules, 2019, through a draft gazette notification, G.S.R. 983(E), dated November 6. The proposal seeks to include antimicrobials in the definition of a new drug under Rule 2(1)(w)(v) of the rules.
If the amendment is finalised, manufacturers would have to obtain permission from the Central Licensing Authority before applying to the concerned State Licensing Authority for a manufacturing licence.
Why the ministry wants the change
The ministry said the proposal was initiated because manufacturing licences for antimicrobial products were being granted without adequate regulatory scrutiny, including studies on bioavailability and bioequivalence and stability.
"The absence of such assessments may affect the quality, safety and efficacy of antimicrobial products. Substandard or ineffective antimicrobials can contribute to the development and spread of antimicrobial resistance, posing risks to patient safety," the ministry said.
Antimicrobial resistance, or AMR, is a major global public health concern. It occurs when bacteria, viruses, fungi and parasites stop responding to the medicines used to treat them, making infections harder to treat and raising the risk of severe illness and death.
The G20 New Delhi Leaders' Declaration underscored the need to address antimicrobial resistance through a One Health approach, which links human, animal and environmental health, the ministry said.
What happens next
The draft notification invites objections and suggestions from stakeholders and members of the public before the Centre considers it for finalisation. The draft is open for public comments for 30 days.
The ministry said the change is expected to strengthen central oversight and help ensure that antimicrobial products entering the market meet appropriate standards of quality, safety and efficacy.
The proposal comes as the ministry launched World AMR Awareness Week 2026, calling for responsible use of antibiotics. Antimicrobials include medicines used to treat or prevent infections, as well as substances applied to skin or surfaces to reduce microbes. They cover antibiotics, antivirals, antifungals and antiparasitics, and are used in people, animals and plants.